louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02033772: Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Congenital Diaphragmatic Hernia
Tracheoesophageal Fistula
Esophageal Atresia
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2014-01-13
Enrollment: 17
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infants \< 6 months of age undergoing thoracoscopic surgery.

Brief summary: The study is primarily a descriptive study examining the physiological, ventilatory, surgical, and recovery effects of patients ≤ 6 months of age who undergo thoracoscopic surgery and to determine the accuracy of transcutaneous CO2 (TC-CO2) and end-tidal CO2 (ET-CO2) during high frequency oscillatory ventilation (HFOV) and thoracoscopic procedures.


Eligibility criteria: Inclusion Criteria:

* Patients presenting for thoracoscopic surgery
* Patients aged ≤ 6 months of age

Exclusion Criteria:

* Patients presenting for any procedure other than thoracoscopic surgery
* Patients aged \> 6 months of age

Primary outcomes:
measure: Change in transcutaneous CO2
timeFrame: Duration of surgery, average of 3 hours.
Secondary outcomes:
measure: Change in ET-CO2
timeFrame: Duration of surgery, average of 3 hours.
measure: Change in heart rate
timeFrame: Duration of surgery, average of 3 hours.
measure: Change in blood pressure
timeFrame: Duration of surgery, average of 3 hours.
measure: Change in SpO2
timeFrame: Duration of surgery, average of 3 hours.
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT06387472: DermAI to Evaluate Human Factor of Testing
Official title: Adaptive Deployment of DermAI to Evaluate Human Factor of Testing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contact Dermatitis
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2024-04-29
Enrollment: 147
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home.


Eligibility criteria: Inclusion Criteria:

- Willing and able to provide informed consent.

Exclusion Criteria:

* Has used topical or oral steroids two weeks prior to patch testing.
* Currently taking immunosuppression agents or is immunocompromised due to medical condition.
* No sunburn or rash at site of testing.
* Women who are breastfeeding or pregnant.
* Treatment with ultraviolet (UV) light (including tanning) during the two weeks prior to visit.
* Subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting patch test area from excess moisture due to showering).

Primary outcomes:
measure: Classification of test site region reaction
timeFrame: 1 week
Secondary outcomes:
measure: Classification of test site region using a 5-point scale
timeFrame: 1 week
measure: False Positive Rate
timeFrame: 1 week
measure: False Negative Rate
timeFrame: 1 week
measure: Early termination of testing
timeFrame: 1 week
measure: Participants that removed patches early
timeFrame: 1 week
measure: Adverse events related to allergen exposure
timeFrame: 1 week
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Matthew Hall, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00740272: Af Ablation In Brady-Tachy Syndrome
Official title: Af Ablation In Brady-Tachy Syndrome
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Brady-tachy Syndrome
Keywords: brady-tachy syndrome
AF ablation
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2008-08-22
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate the impact of atrial fibrillation ablation in patients presenting a brady-tachy syndrome on the AF burden.

The hypothesis of the study is that AF ablation prevents not only from AF episodes recurrence but also from bradycardic episodes.

Detailed description: The study is a randomized study 1:1 AF ablation vs non AF ablation. Patients are followed for 1 year. 38 patients will be required to show a significant reduction in AF burden.

Eligibility criteria: Inclusion Criteria:

* paroxystic AF
* symptomatic pauses (\>5s at night or 3s during daytime)

Exclusion Criteria:

* permanent AF
* age \> 80 y
* pregnant women
* minors

Primary outcomes:
measure: AF burden
timeFrame: 1 year
Secondary outcomes:
measure: Quality of life
timeFrame: 1 year
Other outcomes:
Locations:
city: Marseille
country: France
facility: Hôpital St joseph
city: Rouen
country: France
facility: CHU
city: Toulouse
country: France
facility: Clinique Pasteur
Study officials:
References:
Clinical trial NCT05704972: Investigation of Risk Factors Encountered by Operating Room Nurses
Official title: Investigation of Risk Factors Encountered by Operating Room Nurses
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Work-Related Condition
Lead sponsor: Hasan Kalyoncu University
Sponsor class: OTHER
First posted: 2023-01-30
Enrollment: 154
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Being an operating room nurse

Brief summary: Operating Room Nurses (ORN) are exposed to a lot of risks related to the working environment. There is a limited number of studies describing the risks faced by ADs in the work environment.

Aims: In this study, we aimed to determine the risk factors faced by AHs in operating rooms.

Detailed description: Background: Operating Room Nurses (AH) are exposed to a lot of risks related to the working environment. There is a limited number of studies describing the risks faced by ADs in the work environment.

Aims: In this study, we aimed to determine the risk factors faced by AHs in operating rooms.

Study Design: This is a prospective descriptive study. Methods: The study was carried out with the operating room nurses working in the operating rooms of six hospitals affiliated to the General Secretariat of the Gaziantep Provincial Public Hospitals Association between September 2019 and February 2023.

Eligibility criteria: Inclusion Criteria:

* Volunteer nurse
* Being an operating room nurse

Exclusion Criteria:

• Nurses working outside the operating room

Primary outcomes:
measure: Determining the exposure of ORNs to radiation, biological, ergonomic, chemical, psychological and physical risks in the working environment.
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: 25 December State Hospital
city: Gaziantep
country: Turkey
facility: Gaziantep University Şahinbey Research and Application Hospital
state: Şahinbey
Study officials:
References:
Clinical trial NCT01152372: Experimental Study to Validate the Modified Glucose Disposal Test
Official title: Experimental Medicine Study to Validate the Modified Glucose Disposal Test in Healthy Subjects and Subjects With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2010-06-29
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Evaluate the modified GDT as a measure of key metabolic characteristics in healthy subjects and those with type 2 diabetes mellitus


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Type 2 diabetes
* Clinically healthy
* Drug naive or on a stable dose of metformin monotherapy and/or a secretagogue

Exclusion Criteria:

* Type 1 Diabetes
* History of significant heart disease.
* Bariatric surgery
* Exposure to fibrates, thiazolidinediones, insulin, exenatide, pramlintide or DPP-IV inhibitors

Primary outcomes:
measure: Glucose (labeled and unlabeled), insulin and c-peptide will be measured to calculate insulin sensitivity, endogenous glucose production and insulin secretion
timeFrame: within 24 hours
Secondary outcomes:
measure: Characterize the patterns of intermediate metabolites in healthy subjects and subjects with type 2 diabetes mellitus
timeFrame: within 24 hours
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Profil Institute For Clinical Research, Inc. (Picr)
state: California
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT06686472: Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Official title: A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Allergic Conjunctivitis
Lead sponsor: Telios Pharma, Inc.
Sponsor class: INDUSTRY
First posted: 2024-11-13
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.

The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.


Eligibility criteria: Inclusion Criteria:

* Individuals aged 18 years or older
* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.
* Calculated best-corrected visual activity of 0.7 LogMAR or better
* Positive bilateral CAC reaction

Exclusion Criteria:

* Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study.
* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months
* Any ongoing ocular infection (bacterial, viral or fungal)

Primary outcomes:
measure: Ocular Itching
timeFrame: 3, 5 and 7 minutes after CAC
measure: Conjunctival Redness
timeFrame: 7, 15 and 20 minutes after CAC
Secondary outcomes:
Other outcomes:
Locations:
city: Memphis
country: United States
facility: Telios Investigative Site
state: Tennessee
Study officials:
References:
Clinical trial NCT04412772: Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS
Official title: A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: COVID-19
Lead sponsor: Queen's Medical Center
Sponsor class: OTHER
First posted: 2020-06-02
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The overall objective is to evaluate the clinical efficacy and safety of tocilizumab relative to placebo among approximately 300 hospitalized adult patients who have severe COVID-19. The study will be a 2 arm double blinded comparison between tocilizumab 8 mg/kg and matching placebo IV. The dose may be repeated in 8-12 hours if clinical symptoms worsens, (e.g. increase in oxygen requirements). Participants will be followed for 28 days.


Eligibility criteria: Inclusion Criteria:

* ii. Hospitalized with COVID-19 pneumonia, based on chest X-ray or CT scan AND iii. Evidence of hyperinflammation: IL-6\>40pg/mL (if available) OR CRP \>2 mg/dL OR ferritin \>2000 ng/mL AND iv. One or more of the following: impending need for requiring invasive or non-invasive mechanical ventilation OR shock requiring vasopressor (without evidence of bacterial / fungal infection) OR need for extracorporeal membrane oxygenation (ECMO) OR severe, refractor ARDS (PaO2/FiO2\<200 mmHg)

Exclusion Criteria:

Known severe allergic reactions to tocilizumab or other monoclonal antibodies

* Active tuberculosis infection based on history
* Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
* In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
* Have received oral anti-rejection or immunomodulatory drugs (including tocilizumab) with the past 6 months
* Participating in other drug clinical trials (participation in COVID-19 trials allowed)
* Self-reported pregnant or breastfeeding
* Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 10 x upper limit of normal (ULN) detected within 24 hours at baseline
* Absolute neutrophil count (ANC) \< 1000/mL at baseline
* Platelet count \< 50,000/mL at baseline

Primary outcomes:
measure: Clinical status (on a 7-point ordinal scale) at day 28
timeFrame: up to day 28
Secondary outcomes:
measure: Clinical improvement
timeFrame: up to day 28
measure: Mechanical Ventilation
timeFrame: up to day 28
measure: Oxygenation
timeFrame: up to day 28
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Queen's Medical Center
state: Hawaii
Study officials:
affiliation: The Queen's Medical Center
name: Todd Seto, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02196272: Nurse-led Reminder Program for Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients
Official title: The Efficacy of a Nurse-led Reminder Program on Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Lead sponsor: Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti
Sponsor class: OTHER
First posted: 2014-07-22
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A number of strategies have been evaluated to improve clinical outcomes in diabetics patients, however no studies explored the efficacy of a nurse-led reminder program through email (NRP-e) to improve medication adherence, even if it is fundamental in the management of diabetics. The study aims at evaluating for the first time the efficacy of a nurse-led reminder program through email (NRP-e) to improve medication adherence in diabetic patients.


Eligibility criteria: Inclusion Criteria:

To be elegible, all subjects had to be diabetics (Diabetes Mellitus, Non-Insulin-Dependent)

* Speaking and reading italian
* Having an active phone number and an email address
* Providing a signed a informed consent

Exclusion Criteria:

* Mental illness
* Hospitalized patients and who refused to partecipate

Primary outcomes:
measure: Medication adherence
timeFrame: 6 months
Secondary outcomes:
measure: Trust in nurses
timeFrame: 6 months
measure: Lifestyle
timeFrame: 6 months
measure: Contacts with health services
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04906772: Dexmedetomidine-ketamine Versus Propofol-ketamine for Sedation During Endoscopy in Hepatic Patients
Official title: Dexmedetomidine-ketamine Versus Propofol-ketamine for Sedation During Upper Gastro-intestinal Endoscopy in Hepatic Patients (a Comparative Randomized Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anesthesia; Reaction
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-05-28
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We aim to compare the response to ketamine/dexmedetomidine and ketamine/propofol combinations used in hepatic patients with child-Pugh classification (class A), and early (class B) undergoing UGIE.

Detailed description: 70 Patients will be randomly allocated into two groups; Group (KD): Ketamine/dexmedetomidine (35 patients), will receive IV ketamine 0.25mg/kg and dexmedetomidine1µg/kg over 10 min as loading followed by dexmedetomidine infusion with a rate of 0.5µg/kg/hr and Group (KP): ketamine/propofol (35 patients) will receive IV ketamine 0.25 mg/kg loading and propofol 1 mg/kg over 10 min followed by propofol infusion with a rate of 0.5 mg/kg/hr as a control group.

Eligibility criteria: Inclusion Criteria:

* hepatic patients with child-Pugh classification (class A), and (class B)
* American Society of Anesthesiologists physical status II, III
* aged 18 to 60 years
* scheduled for elective Upper gastro-intestinal endoscopy.

Exclusion Criteria:

* emergency gastro-intestinal endoscopy.
* patients with severe hepatic disorder (Child C) ,
* chronic neuro-psychiatric disorder,
* history of neuro-psychiatric drug intake,
* severe cardiovascular diseases,
* pregnancy,
* history of drug abuse, and
* history of allergy to any of the used drugs in the study

Primary outcomes:
measure: induction time
timeFrame: after 5 minutes from the start of drug infusion till target Ramsay Sedation Score ≥ 3 is reached
measure: Recovery time
timeFrame: after 10 minutes from the stoppage of drug infusion at the end of the procedure till spontaneous eye opening
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of medicine, Ain-Shams university
Study officials:
References:
Clinical trial NCT03229772: Demonstration of the "SPECT/CT System With CZT Detectors" Imaging Performance in a Clinical Setting
Official title: Demonstration of the "SPECT/CT System With CZT Detectors" Imaging Performance in a Clinical Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
First posted: 2017-07-26
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The primary purpose of the study is to obtain sample clinical images that are evaluated by physicians in support of regulatory submissions. Additionally, the study will provide data for current and future product development and it will provide clinical images and data for marketing use.


Eligibility criteria: Inclusion Criteria:

1. are 18-years old and older;
2. is able to sign and date the informed consent form; AND
3. have been prescribed by a physician a nuclear medicine exam that is within the intended use of the device.

Exclusion Criteria:

1. Patients who were referred for dynamic nuclear medicine scan because of the need to be injected twice (once for the conventional acquisition and once for the investigational device) that would result in an increase dose burden on patient.
2. Pregnant or lactating women
3. Who were previously enrolled in this study;
4. Who have contraindication for the radiopharmaceutical
5. Who have any conditions that, in the opinion of the Investigator, would interfere with the evaluation of the results or constitute a health hazard for the subject;

Primary outcomes:
measure: Diagnostic Image Quality
timeFrame: 12 weeks
measure: Image Resolution
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Center
Study officials:
affiliation: Rambam Health Care Center
name: Zohar Keidar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05179772: Olanzapine in OUD Patients
Official title: Olanzapine Augmentation of Buprenorphine-naloxone Treatment in OUD Patients With Comorbid Symptoms of Serious Mental Illness (SMI): A Prospective Open-label Single-arm 9-week Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Opioid Use Disorder
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2022-01-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is designed to examine whether olanzapine (2.5 to 20mg/day) impacts opioid use in patients with opioid use disorder and comorbid SMI symptoms who are taking buprenorphine-naloxone. The specified outcomes (e.g., illicit opioid use, other drug use, sleep, MAT adherence, withdrawal and craving, thought and mood disorder symptoms) on olanzapine will be examined within-subjects for change (improvement) across the trial.

Approximately 48 subjects will be enrolled. After enrollment, subjects will complete safety and baseline assessments and will be assigned open-label to 9-weeks olanzapine. Olanzapine will then be tapered over a 1-week period (or maintained if clinically indicated). Urines will be collected 2x/week throughout.

The study has 4 distinct phases: 1) Screening (approx. 1-2 wks); 2) Baseline and Medication Initiation Visit (1 visit; includes safety, baseline and phenotyping measures, study medication dispensed) 3) Outpatient treatment (9 wks; 2 visits/wk, includes daily olanzapine and daily buprenorphine-naloxone (through the participants usual community treatment site and on-medication phenotyping measures); 4) Follow-up visit (1 wk after last dose of study medication).


Eligibility criteria: Inclusion Criteria:

* meet criteria for opioid use disorder
* have symptoms of SMI
* on stable dose of buprenorphine-naloxone
* females must either be of non-child bearing potential or on highly-effective contraception

Exclusion Criteria:

* abnormal ECG
* cocaine, alcohol, psychoactive use disorders
* metabolic syndrome or diabetes 1 and 2
* history of seizures
* stable regimen of an antipsychotic

Primary outcomes:
measure: Change in illicit opioid use
timeFrame: weeks 3-8
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
Study officials:
affiliation: University of Pennsylvania
name: Kyle Kampman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Pennsylvania
name: Anna Rose Childress, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Virgina Commonwealth University
name: Gerard Moeller, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Virginia Commonwealth University
name: Albert Arias, MD
role: PRINCIPAL_INVESTIGATOR
References: